CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership516,352 shares
Latest Disclosed Value $ 24,562,865
Citadel Advisors Llc ownership in CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 516,352 shares of CRISPR Therapeutics AG (US:CRSP) valued at $24,562,865 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 267,685 shares of CRISPR Therapeutics AG. This represents a change in shares of 92.90% during the quarter. The current value of the position is $26,767,688 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 258,900 of underlying shares valued at $12,315,873 USD and put options representing 572,300 of underlying shares valued at $27,224,311 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 516,352 248,667 92.90 24,563 74.98 0.0040
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 267,685 100,584 60.19 14,037 29.62 0.0021
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 167,101 148,223 785.16 10,830 1,079.63 0.0016
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 18,878 -238,669 -92.67 918 -89.53 0.0002
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 257,547 -621,349 -70.70 8,764 -74.67 0.0017
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 878,896 360,349 69.49 34,593 42.00 0.0060
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 518,547 375,985 263.73 24,361 216.42 0.0047
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 142,562 -94,538 -39.87 7,700 -52.36 0.0016
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 237,100 -36,259 -13.26 16,161 -5.56 0.0031
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 273,359 251,804 1,168.19 17,112 1,649.69 0.0034
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 21,555 -66,410 -75.50 978 -80.19 0.0002
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 87,965 -86,374 -49.54 4,938 -37.37 0.0010
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 174,339 4,425 2.60 7,885 14.16 0.0017
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 169,914 164,324 2,939.61 6,907 1,792.33 0.0016
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,590 -2,618 -31.90 365 -26.85 0.0001
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 8,208 -203,205 -96.12 499 -96.24 0.0001
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 211,413 77,094 57.40 13,270 30.37 0.0027
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 134,319 -83,702 -38.39 10,179 -58.29 0.0021
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS Cmn H17182108 218,021 174,687 403.12 24,403 247.87 0.0051
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 43,334 -232,439 -84.29 7,015 -79.12 0.0016
2021-05-21 2021-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 275,773 209,209 314.30 33,603 229.70 0.0082
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 275,773 209,209 33,603 0.0082
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 66,564 32,291 94.22 10,192 255.49 0.0027
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,273 20,968 157.59 2,867 193.15 0.0008
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS Cmn H17182108 13,305 -19,344 -59.25 978 -29.39 0.0003
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS Cmn H17182108 32,649 -174,609 -84.25 1,385 -89.03 0.0006
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS Cmn H17182108 207,258 207,258 12,623 0.0055
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS Cmn H17182108 0 -61,508 -100.00 0 -100.00
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS Cmn H17182108 61,508 33,233 117.53 1,757 40.11 0.0010
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS Cmn H17182108 28,275 -67,206 -70.39 1,254 -77.65 0.0006
2018-08-14 2018-06-30 13F/A-1 CRISPR THERAPEUTICS Cmn H17182108 95,481 41,785 77.82 5,610 128.61 0.0028
2018-08-10 2018-06-30 13F CRISPR THERAPEUTICS Cmn H17182108 95,481 41,785 5,610
2018-05-14 2018-03-31 13F/A-1 CRISPR THERAPEUTICS Cmn H17182108 53,696 13,885 34.88 2,454 162.46 0.0013
2018-05-11 2018-03-31 13F CRISPR THERAPEUTICS Cmn H17182108 53,696 13,885 2,454
2018-02-09 2017-12-31 13F CRISPR THERAPEUTICS Cmn H17182108 39,811 39,811 935 0.0006
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 258,900 -55.26 12,316 -59.42 n/a n/a n/a
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 578,700 -32.00 30,347 -44.98 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 851,000 -12.79 55,153 16.20 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 975,800 129.33 47,463 227.80 n/a n/a n/a
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 425,500 45.57 14,480 25.86 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 292,300 4.39 11,505 -12.54 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 280,000 -24.53 13,154 -34.35 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 371,000 -23.57 20,038 -39.44 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 485,400 -30.63 33,085 -24.47 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 699,700 79.18 43,801 147.13 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 390,500 14.85 17,725 -7.14 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 340,000 30.22 19,088 61.63 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 261,100 -36.73 11,810 -29.61 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 412,700 -53.64 16,776 -71.16 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 890,200 1.35 58,175 9.00 n/a n/a n/a
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 878,300 83.78 53,374 77.93 n/a n/a n/a
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 477,900 -4.48 29,998 -20.88 n/a n/a n/a
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 500,300 36.28 37,913 -7.73 n/a n/a n/a
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS Cmn Call 367,100 -6.14 41,090 -35.10 n/a n/a n/a
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 391,100 11.84 63,315 48.59 n/a n/a n/a
2021-05-21 2021-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 349,700 23.88 42,611 -1.42 n/a n/a n/a
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 349,700 42,611 n/a n/a n/a
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 282,300 186.02 43,223 423.60 n/a n/a n/a
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 98,700 -24.08 8,255 -13.60 n/a n/a n/a
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS Cmn Call 130,000 56.44 9,554 171.11 n/a n/a n/a
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS Cmn Call 83,100 -15.98 3,524 -41.50 n/a n/a n/a
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS Cmn Call 98,900 -7.83 6,024 36.97 n/a n/a n/a
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS Cmn Call 107,300 5.61 4,398 -8.09 n/a n/a n/a
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS Cmn Call 101,600 29.26 4,785 70.41 n/a n/a n/a
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS Cmn Call 78,600 71.24 2,808 114.19 n/a n/a n/a
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS Cmn Call 45,900 -15.00 1,311 -45.26 n/a n/a n/a
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS Cmn Call 54,000 -32.84 2,395 -49.30 n/a n/a n/a
2018-08-14 2018-06-30 13F/A CRISPR THERAPEUTICS Cmn Call 80,400 263.80 4,724 367.72 n/a n/a n/a
2018-08-10 2018-06-30 13F CRISPR THERAPEUTICS Cmn Call 80,400 4,724 n/a n/a n/a
2018-05-14 2018-03-31 13F/A CRISPR THERAPEUTICS Cmn Call 22,100 1,010 n/a n/a n/a
2018-05-11 2018-03-31 13F CRISPR THERAPEUTICS Cmn Call 22,100 1,010 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 572,300 -24.52 27,224 -31.53 n/a n/a n/a
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 758,200 -14.62 39,760 -30.91 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 888,000 202.66 57,551 303.30 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 293,400 -28.91 14,271 1.61 n/a n/a n/a
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 412,700 -48.00 14,044 -55.04 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 793,700 14.14 31,240 -4.37 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 695,400 -2.17 32,670 -14.90 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 710,800 -14.88 38,390 -32.55 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 835,100 -27.41 56,920 -20.97 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 1,150,500 194.17 72,021 305.71 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 391,100 -4.07 17,752 -22.44 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 407,700 119.43 22,888 172.38 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 185,800 -60.21 8,404 -55.72 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 466,900 104.96 18,979 27.49 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 227,800 -55.84 14,887 -52.52 n/a n/a n/a
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 515,900 9.65 31,351 6.16 n/a n/a n/a
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 470,500 29.05 29,533 6.89 n/a n/a n/a
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 364,600 -8.30 27,629 -37.92 n/a n/a n/a
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS Cmn Put 397,600 -13.55 44,503 -40.23 n/a n/a n/a
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 459,900 26.10 74,453 67.54 n/a n/a n/a
2021-05-21 2021-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 364,700 58.36 44,439 26.03 n/a n/a n/a
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 364,700 44,439 n/a n/a n/a
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 230,300 184.67 35,261 421.15 n/a n/a n/a
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 80,900 -18.28 6,766 -7.01 n/a n/a n/a
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS Cmn Put 99,000 18.99 7,276 106.18 n/a n/a n/a
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS Cmn Put 83,200 8.33 3,529 -24.56 n/a n/a n/a
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS Cmn Put 76,800 123.26 4,678 231.77 n/a n/a n/a
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS Cmn Put 34,400 -12.47 1,410 -23.82 n/a n/a n/a
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS Cmn Put 39,300 -11.09 1,851 17.23 n/a n/a n/a
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS Cmn Put 44,200 -58.26 1,579 -47.82 n/a n/a n/a
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS Cmn Put 105,900 35.94 3,026 -12.42 n/a n/a n/a
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS Cmn Put 77,900 -11.98 3,455 -33.56 n/a n/a n/a
2018-08-14 2018-06-30 13F/A CRISPR THERAPEUTICS Cmn Put 88,500 9.94 5,200 41.30 n/a n/a n/a
2018-08-10 2018-06-30 13F CRISPR THERAPEUTICS Cmn Put 88,500 5,200 n/a n/a n/a
2018-05-14 2018-03-31 13F/A CRISPR THERAPEUTICS Cmn Put 80,500 3,680 n/a n/a n/a
2018-05-11 2018-03-31 13F CRISPR THERAPEUTICS Cmn Put 80,500 3,680 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.